Thelansis

  Adult neuronal ceroid lipofuscinosis (ANCL) is a genetically heterogeneous group of neuronal ceroid lipofuscinoses (NCLs) with onset during the 3rd decade of life, characterized by seizures, dementia and loss of motor capacities, and sometimes associated with visual loss due to retinal degeneration. It is also known as adult NCL, Kufs syndrome, Kufs disease, Parry disease, neuronal ceroid lipofuscinosis, and adult type. The ANCL prevalence is estimated to be about 1.5 people per 9,000,000 in the general population. Thelansis’s “Adult Neuronal Ceroid Lipofuscinosis (ANCL) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Adult Neuronal Ceroid Lipofuscinosis (ANCL) treatment modalities o...